Pardes Biosciences (PRDS) to Be Acquired by MediPacific for $2.02-$2.19 Per Share
by Nicholas Alan Clayton on 2023-07-17 at 8:46am

Pardes Biosciences (NASDAQ:PRDS), which combined with FS Development Corp. II in December 2021, announced that it has agreed to be acquired by MediPacific for $2.02 to $2.19 per share for a premium of 8%-17% over its last closing price.

A tender offer for the company will launch on July 28 to acquire all outstanding Pardes shares within this price range. A MediPacific subsidiary will also receive a contingent value right (CVR) promising it 80% of net proceeds from any license of Pardes assets over the first five years following close.

Pardes’ main drug candidate Pomotrelvir is designed to inhibit the reproduction of coronavirus cells. It demonstrated potential effectiveness in Phase I trials against recent COVID-19 variant Omicron as well as the MERS and SARS variants discovered earlier.

But, its initial readouts from Phase II trials dropped in April and it did not meet its primary endpoint in producing better outcomes than a placebo.

Patients were otherwise healthy, vaccinated adults that had been infected with COVID-19 and although patients in both groups had dropping viral loads and improved health, the data indicated it was likely the vaccine rather than Pomotrelvir doing most of the work.

Pardes stock was in a slump even before these results, however. Having hit a post-close high of $16.88 in January 2022, it has traded below $5 since June 2022, despite being well-funded with just 1.2% redemptions from FS II’s $200 million trust.

But, as the world moved on from COVID, the market appears to have moved on from potential breakthroughs in treating it as well. Having hit an initial dead end with Pomotrelvir’s Phase II, the company announced it would suspend its development and seek out strategic alternatives.

From this standpoint, Pardes may be considered fortunate that it will still be effectively valued at about $130 million in this take-private.

 

Pardes Biosciences (PRDS) to Be Acquired by MediPacific for $2.02-$2.19 Per Share
Recent Posts
by Kristi Marvin on 2025-07-12 at 10:02am

Terms Tracker for the Week Ending July 11, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. One more IPO priced this week bringing July’s total to 8. However, there are still three more weeks left in the month so that number...

by Nicholas Alan Clayton on 2025-07-11 at 8:24am

At the SPAC of Dawn Lately de-SPACs have been announcing corporate moves of a kind frequently in trios as was the case earlier this week when WeBull (NASDAQ:BULL), AST SpaceMobile (NASDAQ:ASTS) and Quantum-Si (NASDAQ:QSI) all announced major equity raises. This week, it is a trio of de-SPACs making reverse stock splits in unison, which is...

by Kristi Marvin on 2025-07-10 at 8:31am

A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...

by Nicholas Alan Clayton on 2025-07-10 at 8:27am

At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...

by Nicholas Alan Clayton on 2025-07-09 at 12:57pm

Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved